Zentalis Pharmaceuticals (ZNTL)
Develops azenosertib for biomarker-selected platinum-resistant ovarian cancer.
$2.80
vs last close−0.28 (−9.25%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 66.27% | 47.50M shares | |
|---|---|---|---|
| 122 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 4.63% | 3.32M shares | |
| 11 holders · as of Jun 18, 2026 | |||
| Strategic holders | 30.41% | 21.79M shares | |
| 2 holders · as of Aug 19, 2026 | |||
| Adds to | 101.31% | ||
71.67M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 101.31%; nothing is left for Other.
13F, as of Jun 30, 2026
122 holders · 47.50M shares · 37 new positions · 65 increased · 32 reduced · 22 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| 5Am Venture Management, LLC | 3.95M | 5.51% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 3.75M | 5.24% | +2.48M | Aug 7, 2026 |
| Squadron Capital Management LLC | 3.70M | 5.16% | +3.30M | Aug 14, 2026 |
| Two Sigma Investments, LP | 3.02M | 4.22% | +68.4K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.84M | 3.96% | +525.0K | Aug 13, 2026 |
| Acadian Asset Management LLC | 2.68M | 3.74% | −166.4K | Aug 13, 2026 |
| Citadel Advisors LLC | 2.30M | 3.21% | +566.3K | Sep 2, 2026 |
| Renaissance Technologies LLC | 1.61M | 2.25% | −329.1K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Walters William T | 19.70% | 13.51M | 13G | Jan 5, 2026 |
| FMR LLCincl. Abigail P. Johnson | 7.14% | 5.08M | Oct 7, 2024 | |
| Barclays PLC | 5.32% | 3.84M | 13G | Nov 12, 2025 |
| BlackRock, Inc. | 5.20% | 3.71M | 13G | Jul 30, 2026 |
| 5AM Opportunities II (GP), LLC | 5.20% | 3.95M | 13G | Dec 30, 2025 |
| Squadron Master Fund LP | 5.10% | 3.68M | 13G | Mar 3, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 14, 2026 | Walters Group10 percent owner | Purchase | 4,335,000 | $3.50 | 17,844,973 |
| Feb 9, 2026 | Julia Marie Eastlanddirector, officer: CEO & President | Sale | 889 | $2.39 | 79,133 |
| Feb 6, 2026 | Julia Marie Eastlanddirector, officer: CEO & President | Sale | 7,866 | $2.43 | 80,022 |
| Feb 10, 2026 | Vincent Vultaggioofficer: PAO and PFO | Sale | 6,894 | $2.42 | 146,506 |
| Feb 9, 2026 | Vincent Vultaggioofficer: PAO and PFO | Sale | 3,379 | $2.39 | 153,400 |
| Feb 6, 2026 | Vincent Vultaggioofficer: PAO and PFO | Sale | 29,951 | $2.43 | 156,779 |
| Feb 9, 2026 | Ingmar Brunsofficer: Chief Medical Officer | Sale | 335 | $2.39 | 33,332 |
| Feb 6, 2026 | Ingmar Brunsofficer: Chief Medical Officer | Sale | 2,962 | $2.43 | 33,667 |
| Feb 3, 2026 | Vincent Vultaggioofficer: PAO and PFO | Sale | 556 | $2.52 | 186,730 |
| Feb 2, 2026 | Vincent Vultaggioofficer: PAO and PFO | Sale | 2,540 | $2.55 | 187,286 |
House and Senate disclosures
Not reported.